Loading...

IBIO IBIO INC Expansion Plans 8-K Filing

B NC

B

IBIO INC

(IBIO)

2026 8-K

Preclinical Data Release

Stock Sale Agreement

Quarterly Results Report

Funding Agreement Details

Annual Shareholder Meeting

Corporate Presentation Update

Quarterly Financial Results

Nasdaq Compliance Regained

New Data Announcement

Financial Results Release

Financial Results Update

Notice of Delisting

Investor Meetings

Debt-Equity Swaps

Financial Statements

License Agreement

Corporate Update

Product Data Release

Earnings Report

Share Placement

Corporate Update

License Agreement

Director Appointments

Financial Results

Corporate Presentation

Financial Results

Departure of Directors or C...

Award Agreements and Code o...

Entry Into a Material Defin...

Termination and Sale

Filing with Quantitative Data

Property Sale and Loan Sett...

Financial Results Announcement

Securities Purchase Agreeme...

Financial Update

Credit and Security Agreement

Regulation FD Disclosure

Credit Agreement Amendment

Public Offering

Securities Purchase Agreeme...

Reverse Stock Split

Agreement Amendment

Agreement Amendment, Financ...

Purchase Agreement with Lin...

Appointment of CEO and CFO

Promissory Note Issued

Regulation FD Disclosure

Credit Agreement Amendment

Regulation FD Disclosure

Amendment to Credit Agreeme...

Management Appointments

Resignation of Officer

External Links:

On March 9, 2026, iBio, Inc. announced that its treatment IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% in a preclinical study involving obese non-human primates. Additionally, the company is expanding into the cardiopulmonary space with new strategies for heart failure treatment.

AI Assistant

IBIO INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.